Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 7/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.61 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | HPGD | P15428 | 7/20 | 0.59 |
| ▸ | GAA | P10253 | 6/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.59 |
| ▸ | GLA | P06280 | 4/20 | 0.54 |
| ▸ | CASP1 | P29466 | 2/20 | 0.54 |
| ▸ | CASP7 | P55210 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL990557 | 0.89 | NOTUM (0.80) | NOTUMPIK3CAPIK3CBALDH1A1HPGD | |
| SCHEMBL12719328 | 0.88 | NOTUM (0.78) | NOTUMPIK3CAPIK3CBALDH1A1HPGD | |
| SCHEMBL991058 | 0.88 | NOTUM (0.78) | NOTUMPIK3CAPIK3CBALDH1A1HPGD | |
| SCHEMBL20597096 | 0.87 | NOTUM (0.78) | NOTUMPIK3CAALDH1A1HPGDGAA | |
| SCHEMBL988463 | 0.83 | NOTUM (0.70) | NOTUMPIK3CAPIK3CBALDH1A1GAA | |
| SCHEMBL20596964 | 0.83 | NOTUM (0.70) | NOTUMPIK3CAPIK3CBALDH1A1GAA | |
| SCHEMBL20597568 | 0.83 | NOTUM (0.70) | NOTUMPIK3CAPIK3CBALDH1A1GAA | |
| SCHEMBL989483 | 0.83 | NOTUM (0.70) | NOTUMPIK3CAPIK3CB | |
| SCHEMBL990576 | 0.82 | NOTUM (0.70) | NOTUMPIK3CAPIK3CBALDH1A1HPGD | |
| SCHEMBL991022 | 0.82 | NOTUM (0.70) | NOTUMPIK3CAPIK3CBALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2276767-B1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2014-05-07 | — | — | EP | claimed |
| EP-2276767-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2011-01-26 | — | — | EP | claimed |
| WO-2009123971-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-10-08 | — | — | WO | claimed |
| US-20090247567-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-10-01 | — | — | US | claimed |
| EP-2714675-B1 | 4H-THIENO[3,2-C]CHROMENE-BASED INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2019-01-02 | — | — | EP | disclosed |
| US-9309265-B2 | Benzopyran and benzoxepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20140336154-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN-LA ROCHE INC. | 2014-11-13 | — | — | US | disclosed |
| US-8846762-B2 | Benzopyran and benzoxepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2276767-B1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-20130123263-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN - LA ROCHE AG (CH) | 2013-05-16 | — | — | US | disclosed |
| US-8399690-B2 | 4,5-dihydro-6-oxa-3-thia-1-aza-benzo[e]azulene compounds | GENENTECH, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110130363-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-7928248-B2 | Benzopyran and benzoxepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| EP-2276767-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009123971-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-10-08 | — | — | WO | disclosed |
| US-20090247567-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336154-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, BMX, PIK3CD | NOTUM 1486/4885PIK3CA 1/4885PIK3CB 9/4885 |
| US-20110130363-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, BMX, PIK3CD | NOTUM 1486/4885PIK3CA 1/4885PIK3CB 9/4885 |
| US-20090247567-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, BMX, PIK3CD | NOTUM 1486/4885PIK3CA 1/4885PIK3CB 9/4885 |
| US-20130123263-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, BMX, PIK3CD | NOTUM 1259/4885PIK3CA 1/4885PIK3CB 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.